PALI-1908
PALI-1908
In Development for the Treatment of Fibro Stenotic Crohn’s Disease
PALI-1908 is a microbiota-activated PDE4 inhibitor prodrug that leverages the advancements we have made with PALI-2108 and is being developed for the treatment of fibro stenotic Crohn’s Disease.
Meets all the criteria of our Precision Delivery platform
- Orally delivered prodrug targets PDE4 inhibition
- De-Risked target verified in multiple significant Phase 2 studies
- Advancing towards CMC development in 2024
- Currently no approved therapies for Fibro Stenotic Crohn’s Disease